Virtus Health an interesting buy
17/11/15 closing share price: $6.110 52 week high: $8.390
Most recent dividend: 14.000c
Annual dividend yield: 4.42%
Australian IVF provider Virtus Health offers an interesting buying opportunity, as identified by both StockLight's quantitative analysis and the qualitative research from Intelligent Investor.
One of Australia's leading IVF providers, it reported earnings per share of 37c in the latest annual report with a return on equity of 11.9%. The fundamentals for the business look attractive.
Virtus performed 15,000 fresh IVF cycles in 2014-15, and with an average charge of $2500 to $5000 per cycle they are achieving an average spend of $13,800 per customer.
The expansion into Asia following its recently launched Singapore operation signals further potential upside and revenue from new diagnostic tests is also starting to bear fruit. Virtus also recently purchased a pathology lab in Sydney, which will increase its range of diagnostic offerings.
"Importantly, this acquisition is central to our strategy to continue to grow our diagnostics offering. With a comprehensive pathology service inhouse and a designated diagnostics division, we will enhance our capacity to introduce new genetics-based testing capabilities - such as Next Generation Sequencing - to both internal and external referrers," said chief executive Sue Channon.
Trading at a price earnings (PE) ratio of 17 with a 4.3% dividend yield, Virtus has "green lighted" by eight of the 10 StockLight healthcare ratios. Intelligent Investor has also issued a buy recommendation on the stock.
Download Australia's premier stocks app for iOS and Android free from stocklight.com